Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Crescent Biopharma reported Q3 2026 financial results and provided clinical updates on its lead programs, including the completion of dose escalation for CR-001 in the Phase 1/2 ASCEND trial. The company expects initial monotherapy data for CR-001 in Q1 2027 and highlighted that over 2,000 patients are expected to be dosed across its portfolio by mid-2027.
Counterparty
Kelun-Biotech
“This has been a defining year for Crescent. We advanced three programs into the clinic and established a leading position in developing next generation IO and ADC combinations which we believe have the potential to redefine cancer care. Together with our partner Kelun-Biotech, we have achieved a remarkable nine IND clearances, and anticipate that more than 2,000 patients will be dosed across our portfolio by mid-2027.”
Joshua Brumm, chief executive officer of Crescent
“The team’s strong execution has positioned us for several meaningful clinical data readouts in 2027, beginning in the first quarter with monotherapy results from our global ASCEND trial of CR-001, including first-line NSCLC patients, followed by initial standard of care chemotherapy combination data from multiple tumor types.”
KinderCare Learning Companies reported third quarter 2026 revenue of $665.3 million, a 1.7% decrease year-over-year, and a net loss of $85.0 million. The results were impacted by lower enrollment at early childhood education centers and $83.4 million in impairment losses related to market capitalization declines and center closures.
“While third-quarter enrollment at KinderCare Learning Centers fell short of our expectations, recent improvements reinforce our confidence in the operational changes we've made.”
Tom Wyatt, Chairman and Chief Executive Officer
“We know families face tough financial choices, and we’re focused on demonstrating the value of KinderCare’s high-quality education and care across all of our brands.”
Horizon Kinetics Holding Corp reported Q3 2026 financial results, including a net loss of $18.4 million primarily driven by unrealized declines in the fair value of key investment holdings. Despite the quarterly loss, year-to-date net income remains positive at $35.8 million, and the company's Board authorized a new $25 million share repurchase program and declared a $0.13 per share dividend.
Mid-America Apartments $350M Debt Financing with U.S. Bank Trust Company, National Association
Mid-America Apartments, L.P. completed the issuance and sale of $350 million in 5.350% Senior Notes due 2031. The notes were issued under an eleventh supplemental indenture with U.S. Bank Trust Company as trustee and will pay interest semi-annually starting June 2027.
Rekor Systems, Inc. reported a decrease in revenue to $10.9 million for the quarter ended September 30, 2026, compared to $14.2 million in the prior year. Despite the revenue decline, the company significantly reduced its net loss to $2.9 million for the quarter, aided by a $3.9 million gain on lease remeasurement and lower overall operating expenses.
Bentley Systems Insider Keith A. Bentley Sells $4.52M of Stock
Keith A. Bentley sold 100,000 shares of Bentley Systems Inc at $45.18 a share, worth $4.52M in total on Nov 10, 2026. Shares held after the trade: 3,745,254 (-2.6%).
TransMedics Group Director James R. Tobin Sells $380K of Stock
James R. Tobin, Director, sold 4,000 shares of TransMedics Group, Inc. at $94.98 a share, worth $380K in total on Nov 9, 2026. Shares held after the trade: 2,922 (-57.8%).
Intellicheck, Inc. reported a net income of $1.77 million for the nine months ended September 30, 2026, a significant improvement from a net loss of $279,000 in the prior year period. Total revenues grew to $17.2 million for the nine-month period, and the company maintained a strong liquidity position with $13.17 million in cash and cash equivalents.
Merlin, Inc. reported Q3 2026 revenue of $3.5 million and GAAP net income of $73.8 million, a significant shift from the prior quarter's loss. The company highlighted new contract wins with USSOCOM and USAFRICOM and stated its 2027 plan aims to reduce operating expenses to extend its cash runway into 2029.
Term
Q3 2026
“The new $8.9 million task order with USSOCOM moves our C-130J autonomy program into its integration phase, laying the groundwork for future flight demonstrations and production revenue with SOCOM and ultimately the global C-130J fleet including hundreds of aircraft.”
Matt George, CEO of Merlin
“the goal of our planning process is to ensure that we not only meet the opportunities presented by our current contracts, but also the broader market potential we detailed on last quarter’s call. We believe that it is imperative for Merlin to continue to advance the Merlin Pilot, but it is also imperative that we demonstrate discipline in the investments we make along the way.”
LGAM Private Credit LLC reported total investment income of $12.3 million for the quarter ended September 30, 2026, and net investment income of $5.4 million. The company's net asset value per unit decreased to $19.35 from $19.93 at the end of 2025, primarily driven by $6.5 million in net unrealized depreciation on investments during the first nine months of the year.
Intellia Therapeutics hosted a webcast for investors and analysts titled 'Readying Lonvo-z for Patients with HAE' to discuss the development and commercialization strategy for its CRISPR-based therapy, lonvoguran ziclumeran. The presentation focused on the clinical data and market potential for lonvo-z in treating hereditary angioedema (HAE).
U.S. Global Investors reported net income of $171,000 for the quarter ended September 30, 2026, a significant decrease from $1.5 million in the prior year period, primarily due to lower net investment income. Operating revenues increased to $2.66 million from $2.25 million, while the company maintained a strong cash position of $25.3 million.
Lucky Strike Entertainment Insider John Alan Young Buys $27.3K of Stock
John Alan Young bought 8,049 shares of Lucky Strike Entertainment Corp at $3.39 a share, worth $27.3K in total on Nov 11, 2026. Shares held after the trade: 113,863 (+7.6%).
Azitra, Inc. reported a net loss of $10.2 million for the nine months ended September 30, 2026, compared to $8.7 million in the prior year period. The company significantly strengthened its cash position to $3.8 million through a $10.4 million private placement and warrant exercises, while continuing to invest heavily in research and development for its synthetic biology dermatology platform.
Merlin, Inc. reported a significant increase in revenue to $3.46 million for the quarter ended September 30, 2026, and achieved a net income of $73.8 million, primarily driven by a $103.6 million gain from the change in fair value of warrant liabilities. Despite the quarterly profit, the company maintains an accumulated deficit of $626.1 million and recorded a net loss of $75.0 million for the nine-month period.
Audax Credit BDC Inc. reported a net increase in net assets resulting from operations of $13.2 million for the nine months ended September 30, 2026, down from $19.7 million in the prior year period. The decrease was primarily driven by higher net realized and unrealized losses on investments totaling $9.7 million and a decline in total investment income to $27.1 million.
TransAct Technologies reported preliminary Q3 2026 financial results with net sales of $14.4 million, up 10% year-over-year, driven by a 33% increase in food service technology revenue. The company reported a net loss of $0.44 million and revised its full-year 2026 revenue guidance downward to $55-$56 million due to softening demand in the Casino and Gaming segment.
Term
Q3 2026
“Our food service technology business drove a strong third quarter, with FST revenue up 33% year-over-year with growth across hardware, software and labels. We sold 2,346 BOHA! units in the quarter, and software revenue grew approximately 61% as pricing actions, new account wins and bundled software packages take hold across our installed base.”
John Dillon, Chief Executive Officer of TransAct
“Casino and Gaming softened in the quarter, consistent with the cyclicality that we have seen in the past, and we expect the softer demand environment to continue into the fourth quarter. However, the fundamentals of this business are unchanged.”
Itt VP & CAO Mesa Graziano Cheryl de Sells $107K of Stock
Mesa Graziano Cheryl de, VP & CAO, sold 500 shares of Itt Inc. at $214.01 a share, worth $107K in total on Nov 10, 2026. Shares held after the trade: 6,659 (-7.0%).
Teva Pharmaceutical Industries President and CEO Richard D. Francis Sells $10.6M of Stock
Richard D. Francis, President and CEO, sold 250,000 shares of Teva Pharmaceutical Industries Ltd at $42.24 a share, worth $10.6M in total on Nov 10, 2026. Shares held after the trade: 927,529 (-21.2%).
For the nine months ended September 30, 2026, Antares Strategic Credit Fund II LLC reported total investment income of $11.0 million and net investment income of $5.3 million. The fund's net asset value per share decreased to $24.76 from $25.28 at the end of 2025, primarily due to net unrealized depreciation on investments and distributions declared.
Arcadia Biosciences reported a net loss of $8.9 million for the nine months ended September 30, 2026, compared to a $1.0 million loss in the prior year, primarily driven by valuation losses on financing activities. Total revenues increased to $4.16 million for the nine-month period, while the company strengthened its cash position to $2.84 million through various inducement offers and PIPE financing.
Obsidian Therapeutics is a clinical-stage biopharmaceutical company focused on developing amsoki-cel (formerly OBX-115). As of November 9, 2026, the company had 61,774,046 shares of common stock outstanding and continues to incur significant financial losses to fund its research and development programs.
Castle Biosciences Chief Commercial Officer Tobin W. Juvenal Sells $207K of Stock
Tobin W. Juvenal, Chief Commercial Officer, sold 6,116 shares of Castle Biosciences Inc at $32.67 to $35.04 a share (average $33.77) in 2 transactions, worth $207K in total between Nov 9, 2026 and Nov 11, 2026. Shares held after the trade: 32,737 (-8.0%).
Silexion Therapeutics Corp effected a 1-for-24 reverse share split of its ordinary shares effective after the close of trading on November 10, 2026. In connection with the split, the company adjusted its outstanding warrants, increasing the exercise price 24-fold to $372,600.00 per post-split share and reducing the number of shares issuable per warrant to 1/24th of a share.
Option Care Health Insider R. Carter Pate Sells $205K of Stock
R. Carter Pate sold 6,492 shares of Option Care Health, Inc. at $31.65 a share, worth $205K in total between Nov 10, 2026 and Nov 11, 2026. Shares held after the trade: 14,128 (-2.8%).
Serina Therapeutics reported third quarter 2026 financial results and provided a clinical update on its SER-252 program for Parkinson's disease. The company has advanced to Cohort 2 of its registrational study following a positive safety review, with topline single-ascending-dose data expected in the first half of 2027.
“We are excited about the achievement of important clinical milestones for SER-252 in Parkinson's disease, advancing from the initial evaluation of our lowest-dose cohort into the next stage of dose escalation. Importantly, the blinded pharmacokinetic observations from Cohort 1 showed the sustained drug exposure SER-252 was designed to achieve, and the independent Safety Monitoring Committee recommended proceeding with continued development.”
Eastman Chemical $300M Debt Financing with Computershare Trust Company, National Association
Eastman Chemical Company issued $300 million in 5.500% Notes due 2030 in a public offering. The notes are general unsecured obligations maturing on February 25, 2030, with interest payable semi-annually. Proceeds are intended for general corporate purposes, which may include the repayment of existing indebtedness.
Advanced Flower Capital Insider Leonard M. Tannenbaum Buys $97.8K of Stock
Leonard M. Tannenbaum bought 29,108 shares of Advanced Flower Capital Inc. at $3.22 to $3.42 a share (average $3.36) in 2 transactions, worth $97.8K in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 7,157,222 (+0.3%).
SoundThinking reported third quarter 2026 financial results with revenue of $25.0 million, which remained flat year-over-year. The company reported a GAAP net loss of $8.5 million, widened from a $2.0 million loss in the prior year, largely due to costs associated with its pending acquisition by Transom Capital Group. The company expects to close the Transom Transaction, which values the company at up to $159 million including contingent value rights, in the fourth quarter of 2026.
Motorola Solutions SVP, COS to the Chairman & CEO Cynthia Yazdi Sells $2.22M of Stock
Cynthia Yazdi, SVP, COS to the Chairman & CEO, sold 4,227 shares of Motorola Solutions, Inc. at $524.59 to $524.78 a share (average $524.60) in 3 transactions, worth $2.22M in total on Nov 9, 2026. Shares held after the trade: 5,417 (-42.5%).